May 17th, 2022 Coherent Market Insights Releases
Insulin is a hormone that lowers blood sugar levels. It may also be necessary in cases of a specific medical condition, such as a surgery. People with type 2 diabetes may also require insulin if other medications haven’t worked. Fortunately, there are many different types of insulin. Some types are fast-acting and help reduce blood glucose quickly after a meal. Others are intermediate or long-acting, and each has its own role to play in balancing blood glucose levels
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4605
Mainly, all traditional insulin are available in the concentration of 100 units/ml, wherein 1 unit equals to around 36 μg of insulin. Insulin can be administered via intravenously or subcutaneously with the help of syringe. Insulin syringes are marked in insulin units and most of the available insulin syringes have 100 units/ml marking. Insulin is most commonly available in concentration of 100 units/ml. Moreover, insulin is also available in concentration: 200 units/ml, 300 units/ml, and 500 units/ml.
Latin America insulin vials market is estimated to be valued at US$ 1,416.4 million in 2021 and is expected to exhibit a CAGR of 8.5% over the forecast period (2021-2028).
Rise in incidence of diabetes is propelling growth of the Latin America insulin vials market
For instance, according to the International Diabetes Federation report 2019, the prevalence of diabetes in Costa Rica is expected to increase from 9.1% in 2019 to 10.3% in 2030 and estimated to reach 11.0% in 2045. Moreover, the same source states that the prevalence of diabetes in Paraguay is expected to increase from 9.6% in 2019 to 10.9% in 2030, and 11.6% in 2045.
The growing research and development activities for the development of more effective insulin for the treatment of diabetes is driving the market growth
For instance, in July 2019, Sanofi S.A., a France-based pharmaceutical company announced positive results for the Phase 3 clinical trial of its new drug Zynquista (sotagliflozin), which is used with insulin to treat adults suffering from type 2 diabetes. Sanofi S.A. also operates in Latin America and new developments of the company in the field of diabetes therapeutics associated with use of insulin are expected to fuel the growth of insulin vial market in Latin America.
The growing diabetes related healthcare expenditure is projected to drive the market growth over the forecast period.
For instance, according to the International Diabetes Federation report 2019, total diabetes related health expenditure in Brazil increased from US$ 4,296.7 million in 2010 to US$ 52,300.2 million in 2019, and is further expected to increase to US$ 60,336.8 million by 2030.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4605
Latin America Insulin Vials Market – Impact of Coronavirus (Covid-19) Pandemic
Government of various countries are focusing on initiatives to fight against the COVID-19 pandemic and stop the spread of the coronavirus infection by implementing various measures in the countries. The Latin American countries such as Brazil have implemented some measures and guidelines such as remote working to reduce the spread of COVID-19 in the country.
Supply chain and manufacturing activities in Latin American countries such as Brazil, Argentina, and others have been disrupted due to lockdowns implemented by governments since the past few months, while countries such as Mexico, Chile, Nicaragua, and others are facing problems with regards to transportation of medical products such as biosimilars, medical devices, and drugs used for treatment of diabetes. This is expected to hamper the growth of Latin America insulin vials market during the COVID-19 pandemic.
For instance, according to the Brazilian National Regulatory Authority, ANVISA (Agência Nacional de Vigilância Sanitária) report 2020, in February 2020, Brazil declared national emergency due to the outbreak of COVID-19 pandemic and later implemented stringent measures and guidelines such as lockdown, social-distancing, remote working, and others. These guidelines will be followed by the pharmaceutical industries, automobile industries, and others, in order to reduce the spread of COVID-19 in Brazil. Thus, COVID-19 pandemic is expected to have a negative impact on the growth of Latin America insulin vials market, owing to lack of labor and restricted supply of goods and materials related to manufacturing and distribution of insulin vials.
Latin America Insulin Vials Market: Restraint
Factor such as high cost of insulin products and side effects such as hypoglycemia and weight gain associated with the use of insulin are hindering growth of the Latin America insulin vials market over the forecast period. For instance, according to the Daily Chronicle report 2019, the price of Lantus, a long-acting insulin manufactured by Sanofi S.A. (operates in Latin America) raised from US$ 289 per vial in 2013 to US$ 431 per vial in year 2019.
Major players operating in the Latin America insulin vials market include Sanofi S.A, Novo Nordisk A/S, and Eli Lilly and Company
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4605
Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Market Analysis by Regions 1.5 Latin America Insulin Vials Market Size Analysis from 2022 to 2028 11.6 COVID-19 Outbreak: Latin America Insulin Vials Industry Impact
Chapter 2 Global Latin America Insulin Vials Competition by Types, Applications, and Top Regions and Countries 2.1 Global Latin America Insulin Vials (Volume and Value) by Type 2.3 Global Latin America Insulin Vials (Volume and Value) by Regions
Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.2 Regional Production Market Analysis
Chapter 4 Global Latin America Insulin Vials Sales, Consumption, Export, Import by Regions (2017-2022) Chapter 5 North America Latin America Insulin Vials Market Analysis Chapter 6 East Asia Latin America Insulin Vials Market Analysis Chapter 7 Europe Latin America Insulin Vials Market Analysis Chapter 8 South Asia Latin America Insulin Vials Market Analysis Chapter 9 Southeast Asia Latin America Insulin Vials Market Analysis Chapter 10 Middle East Latin America Insulin Vials Market Analysis Chapter 11 Africa Latin America Insulin Vials Market Analysis Chapter 12 Oceania Latin America Insulin Vials Market Analysis Chapter 13 South America Latin America Insulin Vials Market Analysis Chapter 14 Company Profiles and Key Figures in Latin America Insulin Vials Business Chapter 15 Global Latin America Insulin Vials Market Forecast (2022-2028) Chapter 16 Conclusions Research Methodology
View Press Release: https://www.coherentmarketinsights.com/press-release/latin-america-insulin-vials-market-3853
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email: sales@coherentmarketinsights.com United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837
Sign up and submit a press release
Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.